FinTechFunding

MGC Pharmaceuticals: Receives approvals for South Africa CimetrA trial

MGC Pharmaceuticals Receives approvals for South Africa CimetrA trial

  • MGC Pharmaceuticals (MXC) receives study and import approvals from the South African Health Products Regulatory Authority for the Phase IIb CimetrA trial
  • The trial will aim to target the effects of viral infections with inflammatory complications in patients with moderate COVID-19
  • Once completed, the trial will provide the data needed to plan future regulatory pathways to register CimetrA as a drug
  • CimetrA is MGC’s natural, immune-modulation formula that is made up of vitamin C and herbal extracts used to treat anti-inflammatory illnesses
  • MGC Pharma is trading 11.1 per cent higher on the market at 2 cents at 2:52 pm AEST
Previous article
Why payments are key to the gaming industry in APAC
Next article
Zeed: Raises £205K in Pre-Seed Funding
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Mastercard to Sell Nets Payments Unit Following $3.2 Billion Acquisition

The divestment follows Mastercard's strategic review of its portfolio. Highlights: Mastercard is set to sell its Nets payments unit.The...
FinTech

Mastercard Seeks to Offload Payments Unit It Acquired for $32 Billion

The proposed sale comes as Mastercard re-evaluates its payments strategy. Highlights: Mastercard aims to sell its payments unit, originally...
FinTech

US FTC Reports Consumers Lost $15.9 Billion to Fraud in 2025

The FTC reveals alarming fraud losses impacting millions of Americans. Highlights: Consumers lost $15.9 billion to fraud in 2025,...
FinTech

EU, UK, and Switzerland Strengthen T1 Testing Plan for 2027 Transition

Three regions collaborate on testing ahead of joint financial move. Highlights: EU, UK, and Switzerland announce T1 testing plan.Collaboration...